CYP2C19 INFLUENCE ON ESCITALOPRAM EFFICACY AND TOLERABILITY IN YOUTH WITH ANXIETY AND DEPRESSION

被引：2
|
作者：
Ramsey, Laura B. [1 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | 2018年 / 57卷 / 10期
关键词：
D O I：
10.1016/j.jaac.2018.07.736
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
21.3
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 50 条
  • [1] Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
    Aldrich, Stacey L.
    Poweleit, Ethan A.
    Prows, Cynthia A.
    Martin, Lisa J.
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [2] CYP2C19 METABOLIZER STATUS IS ASSOCIATED WITH ESCITALOPRAM/CITALOPRAM TOLERABILITY AND RESPONSE IN YOUTH WITH ANXIETY AND DEPRESSIVE DISORDERS.
    Aldrich, S. L.
    Poweleit, E.
    Prows, C. A.
    Martin, L. J.
    Strawn, J. R.
    Ramsey, L. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S69 - S69
  • [3] CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
    de Brito, Rodrigo Bernini
    Ghedini, Paulo Cesar
    HELIYON, 2020, 6 (05)
  • [4] Involvement of CYP2C19 in stress responsiveness, anxiety and depression
    Ingelman-Sundberg, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S119 - S119
  • [5] Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
    Mahajna, Mahmood
    Abu Fanne, Rami
    Berkovitch, Matitiahu
    Tannous, Elias
    Vinker, Shlomo
    Green, Ilan
    Matok, Ilan
    BIOMEDICINES, 2023, 11 (12)
  • [6] Evaluation of pentamidine tolerability and efficacy between CYP2C19 phenotypes
    Koon, Alexis
    He, Jiaxian
    Patel, Jai
    Morse, Allison
    Boseman, Victoria
    Hamilton, Alicia
    Knight, Thomas
    Shah, Nilay
    Ragon, Brittany
    Chojecki, Aleksander
    Ai, Jing
    Steuerwald, Nury
    Gerber, Jonathan
    Copelan, Edward
    Grunwald, Michael
    Arnall, Justin
    PHARMACOGENOMICS, 2023, 24 (15) : 821 - 830
  • [7] CYP2C19 METABOLIZER STATUS PREDICTS ESCITALOPRAM PHARMACOKINETICS IN ADOLESCENTS WITH GENERALIZED ANXIETY DISORDER
    Tulisiak, Anne K.
    Poweleit, Ethan
    Ramsey, Laura A.
    Mills, Jeffrey A.
    Varney, Sara T.
    Mossman, Sarah
    Schroeder, Heidi K.
    Delbello, Melissa P.
    Strawn, Jeffrey Robert
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S247 - S247
  • [8] PHARMACOGENETIC INFLUENCE OF CYP2C19 VARIATION ON ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Poweleit, E.
    Vaughn, S.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S41 - S41
  • [9] Efficacy and tolerability of escitalopram in patients with depression vs depression with comorbid anxiety
    Lampousi, E.
    Stamouli, S.
    Liakouras, A.
    Panagoutsos, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S355 - S356
  • [10] Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram
    Fabbri, C.
    Tansey, K.
    Perlis, R.
    Hauser, J.
    Henigsberg, N.
    Maier, W.
    Mors, O.
    Placentino, A.
    Rietschel, M.
    Souery, D.
    Breen, G.
    Curtis, C.
    Sang-Hyuk, L.
    Newhouse, S.
    Patel, H.
    Guipponi, M.
    Perroud, N.
    Bondolfi, G.
    O'Donovan, M.
    Lewis, G.
    Biernacka, J.
    Weinshilboum, R.
    Farmer, A.
    Aitchison, K.
    Craig, I.
    McGuffin, P.
    Uher, R.
    Lewis, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S582 - S583
12345